News

Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
The U.S. Food and Drug Administration has named Vinay Prasad, an oncologist who has previously criticized FDA leadership and ...
Vinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and ...
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
His new role has caused biotech stocks to drop more than 5% WEDNESDAY, May 7, 2025 (HealthDay News) — The U.S. Food and Drug ...
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics Evaluation and Research, the division that oversees vaccines and ...